Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.800
+0.020 (1.12%)
Aug 21, 2025, 4:00 PM - Market closed
Company Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.
It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair.
Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Biomea Fusion, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Michael J. Hitchcock |
Contact Details
Address: 1599 Industrial Road San Carlos, California 94070 United States | |
| Phone | 650 980 9099 |
| Website | biomeafusion.com |
Stock Details
| Ticker Symbol | BMEA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001840439 |
| CUSIP Number | 09077A106 |
| ISIN Number | US09077A1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael J. M. Hitchcock Ph.D. | Interim Chief Executive Officer and Director |
| Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer and Director |
| Heow Tan | Chief Technology and Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 15, 2025 | EFFECT | Notice of Effectiveness |
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 11, 2025 | SCHEDULE 13G | Filing |
| Aug 5, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | 8-K | Current Report |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 22, 2025 | SCHEDULE 13D/A | Filing |
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| Jun 25, 2025 | SCHEDULE 13G | Filing |